کریمی، ماشاءالله؛ علی‌آبادی، عبدالصمد (1400). واکاوی گستره اباحه مهندسی ژنتیک انسانی (پزشکی و غیرپزشکی) از منظر فقه امامیه. فقه پزشکی، 13(43)، ص1-15.
مرتضوی‌راد، سید حسن و همکاران (1399). تأملی بر رویکرد فقهای امامیه با تاکید بر ادلّه مخالفان اقدامات ژنتیکی. مبانی فقهی حقوق اسلامی (پژوهشنامه فقه و حقوق اسلامی)، 13(25)، ص287-312.
رهنما، حسن؛ سنجریان، فروغ (1390). اخلاق زیستی در مهندسی ژنتیک. اخلاق در علوم و فناوری، 6(3)، ص68-76.
عباسی، محمود؛ شمسی گوشکی، احسان (1389). ملاحظات اخلاقی در پژوهش‌های ژنتیک انسانی. اخلاق پزشکی، 4(11)، ص11-37.
علیدوست، ابوالقاسم؛ حسینی کمال‌آبادی، سید مرتضی (1395). مبانی فقهی مهندسی ژنتیک و محصولات تراریخته. دین و قانون، شماره 14، ص11-48.
Abudayyeh, O.O., Gootenberg, J.S., Konermann, S., Joung, J., Slaymaker, I.M., Cox, D.B.T. & Zhang, F. (2016). C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. Science, 353(6299), aaf5573.
Amoasii, L., Hildyard, J.C.W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D. ... & Olson, E.N. (2018). Gene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy. Science, 362(6410), p. 86-91.
Anzalone, A.V., Randolph, P.B., Davis, J.R., Sousa, A.A., Koblan, L. W., Levy, J.M. ... & Liu, D.R. (2019). Search-and-replace genome editing without double-strand breaks or donor DNA. Nature, 576(7785), p. 149-157.
Araki, M. & Ishii, T. (2014). International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reproductive Biology and Endocrinology, 12(1), p. 108. https://doi.org/10.1186/1477-7827-12-108
Baylis, F. (2019). Altered inheritance: CRISPR and the ethics of human genome editing. Harvard University Press.
Brokowski, C. & Adli, M. (2019). CRISPR ethics: Moral considerations for applications of a powerful tool. Journal of Molecular Biology, 431(1), p.1-7.
https://doi.org/10.1016/j.jmb.2018.05.044
Buchanan, J., Smith, A. & Johnson, R. (2000). Understanding organizational behavior. New York, NY: Academic Press.
Cyranoski, D. (2019). China tightens rules on gene editing in humans. Nature, 566(7745), p.15.
Deuse, T., Hu, X., Gravina, A., Wang, D., Tediashvili, G., De, V.L. ... & Schrepfer, S. (2019). Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nature Biotechnology, 37(3), p. 252-258. https://doi.org/10.1038/s41587-019-0016-3
Doudna, J.A. & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213).
Esvelt, K.M., Smidler, A.L., Catteruccia, F. & Church, G.M. (2014). Concerning RNA-guided gene drives for the alteration of wild populations. eLife, no. 3, e03401.
European Commission. (2020). Ethics in science and new technologies.
URL= https://ec.europa.eu/research/science-society/document_library/pdf_06/ethics-in-science-and-new-technologies_en.pdf
European Medicines Agency. (2021). Annual report 2020. European Medicines Agency. URL= https://www.ema.europa.eu/en/documents/annual-report/annual-report-2020_en.pdf
Evans, J.H. & Evans, M.S. (2016). Science and the public: The need for trust and transparency. Cambridge University Press.
FDA. (2020). Gene therapy.
Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., & Sander, J.D. (2013). High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells. Nature Biotechnology, 31(9), p. 822-826.
Ginn, S.L., Amaya, A.K., Alexander, I.E., Edelstein, M. & Abedi, M.R. (2018). Gene therapy clinical trials worldwide to 2017: An update. Journal of Gene Medicine, 20(5), p. e3015. https://doi.org/10.1002/jgm.3015
Gostin, L.O., Hodge, J.G. & Bloom, B.R. (2019). The public health crisis of underimmunisation: A global plan of action. The Lancet Infectious Diseases, 19(2), p. 119-124.
https://doi.org/10.1016/S1473-3099(18)30608-1
Greely, H.T. (2019). CRISPR people: The science and ethics of editing humans. MIT Press.
Hurlbut, J.B., Jasanoff, S. & Saha, K. (2017). CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology, 33(4), p. 33-38.
Isasi, R., Kleiderman, E. & Knoppers, B.M. (2016). Editing policy to fit the genome? Science, 351(6271), p. 337-339.
Jasanoff, S. (2011). Designs on nature: Science and democracy in Europe and the United States. Princeton University Press.
Jasanoff, S., Hurlbut, J.B. & Saha, K. (2015). CRISPR democracy: Gene editing and the need for inclusive deliberation. Issues in Science and Technology, 32(1), p. 33-38.
Kimmelman, J., Baylis, F. & Glass, K.C. (2017). Research ethics in the era of CRISPR. Science, 356(6336), p. 45-47.
Knoepfler, P. (2017). GMO sapiens: The life-changing science of designer babies. World Scientific Publishing
Koonin, E.V., Makarova, K.S. & Zhang, F. (2017). Diversity, classification and evolution of CRISPR-Cas systems. Current Opinion in Microbiology, no. 37, p. 67-78.
Lander, E., Baylis, F., Zhang, F., Charpentier, E., Berg, P., Bourgain, C. ... & Zhou, Q. (2019). Adopt a moratorium on heritable genome editing. Nature, 567(7747), p. 165-168.
Ledford, H. (2020). CRISPR gene editing in human embryos wreaks chromosomal mayhem. Nature, 583(7818), p. 17-18. https://doi.org/10.1038/d41586-020-01906-4
Maude, S.L., Laetsch, T.W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H. ... & Grupp, S.A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), p. 439-448.
https://doi.org/10.1056/NEJMoa1709866
National Academies of Sciences, Engineering, and Medicine. (2017). Human genome editing: Science, ethics, and governance. National Academies Press.
National Institutes of Health. (2019). Statement on NIH funding of research using gene-editing technologies in human embryos.
URL= https://www.nih.gov/news-events/digital-media-kits/gene-editing
Normile, D. (2019). China sprints ahead in CRISPR therapy trials. Science, 365(6458),
p. 1204-1205.
Savulescu, J., Pugh, J., Douglas, T. & Gyngell, C. (2015). The moral imperative to continue gene editing research on human embryos. Protein & Cell, 6(7), p. 476-479.
Scheufele, D.A., Xenos, M.A., Howell, E.L., Rose, K.M., Brossard, D. & Hardy, B.W. (2017). U.S. attitudes on human genome editing. Science, 357(6351), p. 553-554.
https://doi.org/10.1126/science.aan3708
Sheridan, C. (2019). FDA approves first CAR-T therapy. Nature Biotechnology, 35(8),
p. 697-698.
UNESCO. (2015). Report of the International Bioethics Committee (IBC) on updating its reflection on the human genome and human rights.
URL= https://unesdoc.unesco.org/ark:/48223/pf0000233258
United Nations. (2020). The right to science: A global report on human genome editing and human rights. United Nations Human Rights Council.
Wei, X. & Nielsen, R. (2019). CCR5-∆32 is deleterious in the homozygous state in humans. Nature Medicine, 25(6), p. 909-910. https://doi.org/10.1038/s41591-019-0459-6
World Health Organization. (2019). WHO issues new recommendations on human genome editing for the advancement of public health. URL= https://www.who.int/health-topics/human-genome-editing/ensuring-responsible-use-of-life-sciences-research
Zhou, M., Greenhill, S., Huang, S., Silva, T.K., Sano, Y., Wu, S. ... & Silva, A.J. (2016). CCR5 is a suppressor for cortical plasticity and hippocampal learning and memory. eLife, no. 5, e20985.
